The metabolic effects of antipsychotics in the early stage of treatment in first-episode patients with schizophrenia: A real-world study in a naturalistic setting
Authors:
- 1 October 2020
- journal article
- research article
- Published by Elsevier in Journal of Psychiatric Research
- Vol. 129, 265-271
Abstract
No abstract availableKeywords
Funding Information
- National Nature Science Foundation of China (81630030, 81920108018)
- National Key R & D Program
- Ministry of Science and Technology, China (2016YFC0904300)
- Department of Science and Technology of Sichuan provincial government (2019YFS0153)
- 1.3.5 project for disciplines of excellence
- West China Hospital of Sichuan University (ZY2016103, ZY2016203, ZYGD20004)
This publication has 36 references indexed in Scilit:
- Antipsychotic drugs and obesityTrends in Molecular Medicine, 2011
- Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysisSchizophrenia Research, 2010
- Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009Diabetologia, 2010
- Effects of Olanzapine and Risperidone on Glucose Metabolism and Insulin Sensitivity in Chronic Schizophrenic Patients With Long-Term Antipsychotic TreatmentThe Journal of Clinical Psychiatry, 2009
- Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC)European Psychiatry, 2009
- Which comes first: atypical antipsychotic treatment or cardiometabolic risk?Acta Psychiatrica Scandinavica, 2009
- Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemiaJournal of Psychopharmacology, 2007
- Schizophrenia and increased risks of cardiovascular diseaseAmerican Heart Journal, 2005
- The Metabolic Syndrome: Requiescat in PaceClinical Chemistry, 2005
- Impaired Fasting Glucose Tolerance in First-Episode, Drug-Naive Patients With SchizophreniaAmerican Journal of Psychiatry, 2003